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Abstract
Cytarabine and daunorubicin are old drugs commonly used in the treatment of acute 
myeloid leukaemia (AML). Refractory or relapsed disease because of chemotherapy 
resistance is a major issue. microRNAs (miRNAs) were incriminated in resistance. This 
study aimed to identify miRNAs involved in chemoresistance in AML patients and to 
define their target genes. We focused on cytogenetically normal AML patients with 
wild-type NPM1 without FLT3-ITD as the treatment of this subset of patients with 
intermediate-risk cytogenetics is not well established. We analysed baseline AML 
samples by small RNA sequencing and compared the profile of chemoresistant to 
chemosensitive AML patients. Among the miRNAs significantly overexpressed in 
chemoresistant patients, we revealed miR-15a-5p and miR-21-5p as miRNAs with a 
major role in chemoresistance in AML. We showed that miR-15a-5p and miR-21-5p 
overexpression decreased apoptosis induced by cytarabine and/or daunorubicin. 
PDCD4, ARL2 and BTG2 genes were found to be targeted by miR-15a-5p, as well as 
PDCD4 and BTG2 by miR-21-5p. Inhibition experiments of the three target genes 
reproduced the functional effect of both miRNAs on chemosensitivity. Our study 
demonstrates that miR-15a-5p and miR-21-5p are overexpressed in a subgroup of 
chemoresistant AML patients. Both miRNAs induce chemoresistance by targeting 
three pro-apoptotic genes PDCD4, ARL2 and BTG2.
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1  | INTRODUC TION
Acute myeloid leukaemia (AML) is a heterogeneous group of clonal my-
eloid neoplasms with still a poor prognosis.1 For several decades, the 
standard of care for AML patients has been the classical “7 + 3” regi-
men combining 7 days of cytarabine and 3 days of an anthracycline.2,3 
During these years, the incremental improvements in AML patient 
overall survival that were observed were mainly because of better sup-
portive care. Unfortunately, up to 30%-40% of patients will develop a 
chemorefractory disease, defined as failure to achieve morphological 
complete response (CR) after one to two cycles of induction chemo-
therapy. This subgroup of AML patients faces a dismal prognosis with 
a median survival of <1 year.4,5 To decipher underlying mechanisms of 
resistance to induction chemotherapy in AML, a better understanding 
of the heterogeneity of refractory patients at the cellular and molec-
ular levels is critical. The development of novel therapies is very much 
needed to improve outcome of chemoresistant AML patients.
Acute myeloid leukaemia is the result of a clonal multistep evolu-
tionary process starting with the acquisition of founder mutations in 
the haematopoietic stem cell followed by driver mutations ultimately 
leading to the development of AML.2 The cause of drug resistance can 
be intrinsic in patients who fail the initial chemotherapy because of 
the presence of multiples subclones or acquired after chemotherapy 
through the selection or acquisition of mutations in resistant subclones. 
Several pathways were altered in resistance including DNA damage 
and repair, cell cycling, cell death, drug targets, drug metabolism and 
drug trafficking.6,7 Targeted therapies directed to the chemotherapy 
resistance mechanisms may improve the outcome for these patients.
microRNAs (miRNAs) constitute a class of short, evolutionary 
conserved, non-coding RNAs with major regulatory functions. miR-
NAs can regulate up to 60% of protein-coding genes. By binding to 
the 3′ untranslated region of target mRNAs, a single miRNA can neg-
atively regulate the expression of a wide variety of target genes (up 
to 200 mRNAs). miRNA expression was found deregulated in human 
cancers and in particular in AML.8,9 Each AML subtype exhibits a 
unique miRNA signature.8 Several studies showed that miRNA can 
function as tumour suppressor or onco-miRNAs according to the 
roles of their target genes.10 miRNAs can affect crucial leukaemic 
processes such as proliferation, survival, differentiation, self-re-
newal, epigenetic regulation, in vivo disease progression and che-
motherapy resistance. Modifying miRNA expression is an exciting 
potential therapeutic approach in AML. Because miRNA can repress 
several targets involved in different pathways, miRNA-based ther-
apy would be an efficient tool against chemoresistance.
microRNAs were reported to regulate sensitivity and resistance 
to cytotoxic agents in AML cell lines.7,11 Increased expression of some 
miRNAs resulted in chemosensitivity, whereas others were linked to 
chemoresistance. The mechanisms whereby miRNAs cause chemo-
resistance in AML patients are not well understood. Equally unclear 
are the molecular bases for differential expression of miRNAs in his-
tologically and genetically similar AMLs. Understanding how miRNAs 
are differently expressed, their targets and effects on the AML clone 
might also help to better understand the leukemogenesis process.
In the current study, we assessed whether miRNAs play a role 
in chemoresistance in cytogenetically normal AML patients treated 
with standard induction chemotherapy. We analysed miRNA expres-
sion by high-throughput small RNA sequencing in two cohorts of 
AML patients. Next, we performed functional tests on cell lines and 
identified target genes involved in chemoresistance. These results 
pave the way for therapeutic interventions to circumvent chemo-
therapy resistance.
2  | MATERIAL S AND METHODS
2.1 | Patient samples
Frozen diagnostic bone marrow RNA samples were obtained from 
47 adults who had a confirmed diagnosis of AML. Twenty-seven 
of these patients were considered “chemosensitive” because they 
reached CR after receiving one cycle of induction chemotherapy. 
The twenty remaining patients were considered “chemoresistant”, 
defined as more than 5% blast cells in the bone marrow after in-
duction chemotherapy. Cytogenetic analyses were performed at 
diagnosis. FLT3-ITD and NPM1 mutation analysis was performed 
by PCR amplification and sequencing. Patients with a cytogeneti-
cally normal AML (CN-AML) and wild-type NPM1 without FLT3-
ITD were included in the study (Table S1). TP53, ASXL1 and RUNX1 
mutational status was obtained for 37 patients by next-genera-
tion sequencing (Illumina TruSight Myeloid Panel) as previously 
described.12
Patient clinical characteristics are shown in Table S1.
Blasts and mononuclear cells at diagnosis were purified by Ficoll-
Hypaque (Nygaard) density gradient centrifugation and cryopre-
served. RNA was isolated with either RNA-Bee or RLT following the 
protocols of the manufacturer (Bio-Connect BV). Frozen diagnostic 
bone marrow RNA samples were analysed by small RNA sequencing.
2.2 | Small RNA sequencing
Multiplexed patient libraries (TruSeq small RNA) were prepared and 
sequenced within the same flow cell (HiSeq 2000 PE 2 × 50 bp se-
quencing). Samples were run in the Genomic Core Lab Facility in UZ 
Leuven.
See supplemental methods (Appendix S1) for details.
2.3 | Cell lines
The human AML cell lines K562 and OCI-AML3 (purchased from 
DSMZ) were cultured in RPMI 1640 supplemented with 10% foetal 
bovine serum and in Alpha-MEM with 20% foetal bovine serum, re-
spectively, and with 50 U/mL penicillin and 50 mg/mL streptomycin 
(Gibco). Cells were treated with cytarabine (Ara-C; Sigma #C1768), 
daunorubicin (DNR; Sigma #W4013) or vehicle (water or DMSO). 
     |  577VANDEWALLE Et AL.
K562 cells were treated with daunorubicin 0.5 µmol/L and/or cyt-
arabine 5 µmol/L for 24 hours. OCI-AML3 cells were treated with 
daunorubicin 0.1 µmol/L and/or cytarabine 1 µmol/L for 24 hours as 
these cells are more sensitive to chemotherapy.
2.4 | Generation of stable miRNA-expressing cell 
lines using lentiviral infection
The lentiviral-expressing vector of endogenous miR-15a and miR-
21 human pre-miRNAs was purchased from Systems Biosciences 
(# PMIRH15aPA-1 and PMIRH21PA-1). See supplemental methods 
(Appendix S1) for details.
The efficiency of the infection was checked by measuring the 
green fluorescent protein (GFP) expression by flow cytometry and 
was around 88% and 72% in K562 and OCI-AML3, respectively, as 
shown in Figure S1A. miRNA mature expression was measured by 
qRT-PCR (Figure S1B). An empty vector was used as control.
2.5 | Transient transfection
The synthetic miRVana™ hsa-miR-15a-5p mimic (#MC10235) and 
miRVana™ hsa-miR-21-5p mimic (#MC10206) were purchased 
from Life Technologies. A total of 5 million of K562 cells were nu-
cleoporated using Amaxa® Nucleofector® Technology (Lonza) with 
100 µL of solution V (#VCA-1003; Program T-016) with 500 pmol 
of precursor oligonucleotide. The transfection efficiency of K562 
cells using this method is close to 90%. miR-15a-5p and miR-21-5p 
expression levels after transfection without and with daunorubicin 
and cytarabine treatment are shown in Figure S2. Scrambled oligo-
nucleotides were used as control.
2.6 | Functional assays
Annexin V (V450)—BV421 stain (BD Biosciences Pharmingen; 
#563973)—was performed 24h after the treatment and measured 
using FACSVerse.
2.7 | Microarray studies on cell lines
Microarrays were performed according to the Affymetrix® WT 
PLUS standard protocol following the manufacturer’s instructions.
See supplemental methods (Appendix S1) for details.
2.8 | Quantitative reverse transcription polymerase 
chain reaction
For the quantification of miRNA levels after lentiviral infections, re-
verse transcription was carried out using the QuantiMir Reverse 
Transcription Kit (System Biosciences, #RA420A-1) and real-time PCR 
was performed using the designed forward primer, the universal re-
verse primer, the SYBR Green qPCR Master Mix and the Quantimir 
cDNA according to the manufacturer’s instructions. Normalization was 
completed with U6. Comparative real-time polymerase chain reaction 
(PCR) was performed in triplicate. Quantitative data were calculated 
using a regression curve from serial dilutions of a standard cDNA.
For the quantification of miRNA levels in other experiments, 
50 ng of total RNA was used for reverse transcription, using TaqMan 
MicroRNA Reverse Transcription Kit (Life Technologies) and re-
al-time PCR was performed using the TaqMan MicroRNA Assay Kit 
(Life Technologies; miR-15a-5p #000397 and miR-21-5p #000389) 
according to the manufacturer's instructions. Normalization 
was completed with small nucleolar RNU44 (Life Technologies; 
#001094). Relative expression was calculated using the comparative 
cross-threshold (Ct) method.
For the quantification of mRNA levels, 1 µg of total RNA was used 
for reverse transcription, using MMLV (Moloney murine leukaemia 
virus) reverse transcriptase enzyme (Invitrogen). We used TaqMan 
Gene Expression assays (Life Technologies; PDCD4 #Hs00377253, 
ARL2 #Hs00155873, BTG2 3Hs0019888). GAPDH served as nor-
malization control (Life Technologies; Hs02758991). Comparative 
real-time PCR was performed in triplicate. Relative expression was 
calculated using the comparative cross-threshold (Ct) method.
2.9 | Western blotting
Total protein extracts from K562 cells transfected with synthetic 
miRNAs and scrambled oligonucleotides were extracted using lysis 
buffer (25 mm Tris-HCl, pH 7.4, 150 mmol/L NaCl, 6 mmol/L EDTA, 
10% glycerol and 1% Triton X-100) containing protease inhibitors 
(1 mmol/L Pefabloc®, 1.7 μg/mL aprotinin and 1 mmol/L ortho-
vanadate de sodium). Protein expression was analysed by Western 
blotting using PDCD4 (Santa Cruz, sc#130545) and ARL2 (Abcam, 
ab#109742) antibodies as previously described.13
2.10 | Luciferase reporter experiments
The 3′UTR segments containing the target sites for miR-15a-5p and 
miR-21-5p were amplified by PCR from cDNA and inserted into pGL3 
control vector (Promega), using the Xba1 site.
See supplemental methods (Appendix S1) for details.
2.11 | Gene expression profiles of patient samples
Expression levels of the three target genes—PDCD4 (1557166 at, 
202730 s at, 202731 at, 212593 s at, 212594 at), ARL2 (202564 x 
at) and BTG2 (201235 s at, 201236 s at)—were analysed in 43 on a 
total of 47 patient samples by using Affymetrix U133A GeneChips 
as previously described.14
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2.12 | PCA and correlation studies
A principal component analysis (PCA) using gene and miRNA expres-
sion data for the selected miRNAs (miR-15a-5p and miR-21-5p) and 
probesets of PDCD4, ARL2 and BTG2 genes was performed in R pro-
gram using the mixOmics package.15 Chemoresistant patient numbers 
59, 61, 62 and 63 were removed from the PCA because we did not 
have enough RNA left to perform gene expression profiles. To study 
the correlation between genes and miRNAs that were the basis of this 
PCA, correlation plot was generated from the PCA. Normal regres-
sion analysis was performed between the clinical data and the patient 
loadings on the three first PCs. Each clinical phenotype (bone marrow 
blast percentage, white blood cell count, platelet count) was evalu-
ated individually against the patient loading on the three PCs.
2.13 | siRNA transfections
A total of 5 million of K562 cells were nucleoporated using Amaxa® 
Nucleofector® Technology (Lonza) with 100 µL of solution V (#VCA-
1003; Program T-016) with 50 nmol/L anti-PDCD4 (# L-004438-
00-0020) and with 50 nmol/L anti-ARL2 (# L-011585-00-0020) and 
with 50 nmol/L anti-BTG2 (# L-012308-00-005) compared with a 
control (non-targeting siRNA #1 #D-001810-01-20) (Dharmacon, 
SMARTpool siRNAs or control). The efficiency of the siRNAs was 
evaluated by Western blotting for PDCD4 and ARL2 and by qRT-
PCR for the three target genes at 24 hours (Figure S3).
3  | RESULTS
3.1 | miR-15a-5p and miR-21-5p are overexpressed in 
chemoresistant AML patients
To identify miRNAs that are involved in chemoresistance, we first 
analysed miRNA expression in bone marrow samples from 47 AML 
patients at diagnosis, before treatment with cytarabine and anthra-
cycline, using Illumina small RNA sequencing. We selected samples 
from patients younger than 65 years with cytogenetically normal 
AML (CN-AML) and wild-type NPM1 without FLT3-ITD. This sub-
group of AML patients was included in the intermediate-risk cate-
gory by the 2010 ELN genetic risk stratification.16 The consolidation 
therapy of the intermediate-risk genetics category is not well estab-
lished. The three options proposed by the ELN are intensive chem-
otherapy, high-dose therapy followed by autologous or allogeneic 
haematopoietic stem cell transplantation.3,16
We compared pre-treatment miRNA expression in chemosensi-
tive (n = 27) and chemoresistant (n = 20) patients. Relevant miR-
NAs were sorted based on three criteria (their relative linear fold 
change, area under the ROC curve and frequency of random forest 
feature selection) as computed by the procedures explained in ma-
terial and methods. Table S3 showed the list of miRNAs differentially 
expressed between both groups of patients with a highly significant 
P-value (≤10E-08) and a frequency of selection of 100%.
We selected the four miRNAs of this list with a linear fold change 
above 7 (Table 1).
Figure 1A shows the distribution of the expression of miR-21-5p, 
miR-340-5p, miR-181c-5p and miR-15a-5p. The distribution confirmed 
the difference between both groups of patients. We validated the 
significant differential expression of two of these miRNAs—miR-
15a-5p and miR-21-5p—by qRT-PCR in patient samples (Figure 1B). 
We did not find a significant differential expression of miR-340-5p 
and miR-181c-5p between the two groups of patients by qRT-PCR 
(data not shown).
The more recent ELN2017 genetic risk stratification specified 
that this subgroup of AML patients with wild-type NPM1 and no 
FLT3-ITD (or with FLT3-ITD low) was classified in the intermedi-
ate-risk category if they did not have any adverse-risk genetic lesion. 
We collected the mutational status for RUNX1, ASXL1 and TP53 in 
eighty percent of our patients and excluded the patients with RUNX1 
or ASXL1 mutation. TP53 mutation was not found in our patients. 
The overexpression of miR-21-5p and miR-15a-5p in chemoresistant 
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18.65 2.50E-014 4.26 0.833 100 Yes
hsa-miR-340-5p 
(MIMAT0004692)
11.79 2.59E-011 3.6 0.846 100 No
hsa-miR-181c-5p 
(MIMAT0000258)
7.62 7.99E-008 3.26 0.817 100 No
hsa-miR-15a-5p 
(MIMAT0000068)
7.21 2.15E-011 3.22 0.886 100 Yes
Note: The selection frequency represents the number of times a miRNA was ranked among the top 30 selected features discriminating the resistant/
sensitive phenotype by the leave-one-out cross-validated random forest model, using the absolute T statistics ranking.
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AML patients regarding chemosensitive patients was confirmed in 
our smaller cohort of patients classified in the intermediate-risk cat-
egory following the ELN2017 genetic risk stratification (Figure S4).
We compared patient clinical characteristics at diagnosis (bone 
marrow blast percentage, white blood cell count, platelet count) in 
chemoresistant and chemosensitive AML patients (Table S1). The re-
gression analysis did not show any significant correlation between 
the clinical characteristics and miR-21a-5p or miR-15a-5p expression 
level or the chemoresistance (data not shown).
3.2 | miR-15a-5p and miR-21-5p reduce apoptosis 
induced by cytarabine and daunorubicin
The expression of miR-15a-5p and miR-21-5p was first measured by 
qRT-PCR in K562 and OCI-AML3 cell lines. miR-21-5p was expressed 
at a higher level than miR-15a-5p in both cell lines. The treatment of 
K562 or OCI-AML3 with daunorubicin or with cytarabine did not 
significantly change miR-15a-5p or miR-21-5p expression (Figure S5).
To evaluate the impact of miR-15a-5p and miR-21-5p on chemo-
sensitivity, we stably overexpressed both miRNAs in the cell lines 
(K562 and OCI-AML3) using a lentiviral construct containing the 
pre-miR-15a-5p or pre-miR-21-5p. The empty lentivirus was used as 
control. The efficiency of the infection was measured by analysing 
the GFP expression by flow cytometry and miRNA mature expres-
sion by qRT-PCR (Figure S1). Infected cells were treated with cytar-
abine and/or daunorubicin for 24 hours. As shown in Figure 2, the 
overexpression of miR-15a-5p or miR-21-5p significantly decreased 
apoptosis induced by the combination of cytarabine and daunoru-
bicin in K562. The overexpression of miR-15a-5p or miR-21-5p also 
decreased apoptosis induced by cytarabine alone or by daunorubicin 
alone (Figure S6). Like in K562, in OCI-AML3, the overexpression 
of either miRNAs decreased apoptosis induced by cytarabine and 
daunorubicin alone or combined (Figure S7).
As a note, note that the overexpression of miR-15a-5p or miR-
21-5p did not lead to a significant reduction in apoptosis in the ab-
sence of chemotherapy in both cell lines (Figure S8).
Remarkably, enforced expression of miR-15a-5p and miR-21a-5p 
by lentiviral infection caused only a 5- to 7-fold increase in expres-
sion of miRNAs, which was comparable to the difference in expres-
sion that we observed between chemosensitive and chemoresistant 
patients. Our observations suggest that a 5- to 7-fold change in miR-
15a-5p and miR-21-5p expression was sufficient to play an important 
role in apoptosis and chemoresistance.
F I G U R E  1   miR-21-5p, miR-340-5p, miR-181c-5p and miR-15a-5p are overexpressed in chemotherapy-resistant AML patients. A, Expression 
of miR-21-5p, miR-340-5p, miR-181c-5p and miR-15a-5p was analysed by small RNA sequencing in AML patients, with normal karyotype, 
sensitive (n = 27) or resistant (n = 20) to the standard chemotherapy combining cytarabine and daunorubicin. The box plot is based on 
geometric mean (log10 CPM). P values were obtained using a t test. *** Indicates a significant difference P ≤ .001. B, Expression of miR-15a-
5p and miR-21-5p was analysed by qRT-PCR in AML patients, with normal karyotype, sensitive (n = 27) or resistant (n = 20) to standard 
chemotherapy treatment combining cytarabine and daunorubicin. The box plot is based on geometric mean (log10). P values were obtained 
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3.3 | miRNA target genes involved in 
chemoresistance
To investigate potential miR-15a-5p and miR-21-5p target genes in-
volved in chemoresistance, we overexpressed each miRNA in K562 
cell line and simultaneously treated the cells with daunorubicin using 
a concentration of 1 µmol/L. Synthetic miRNA oligonucleotides and 
controls (scrambled oligonucleotides) were transfected in K562 
using nucleoporation. The transfection efficiency was controlled 
24 hours after transfection by measuring miRNA expression using 
qRT-PCR (data not shown). Gene expression profiles were deter-
mined 24 hours after transfection and daunorubicin treatment by 
using Affymetrix microarrays. The lists of down-regulated mRNAs 
were crossed with target genes identified by bioinformatic predic-
tion programs (PicTar and TargetScan). We found 30 genes that were 
down-regulated by miR-21-5p and were predicted as target genes by 
PicTar and TargetScan (Table S4). After overexpression of miR-15a-
5p, we found 141 down-regulated genes that were predicted as tar-
get genes by both programmes (Table S4). The most down-regulated 
genes were BTG2 and PDCD4 after overexpression of both miRNAs, 
and ARL2 after overexpression of miR-15a-5p only (Table 2).
To validate these three potential miR-15a-5p and miR-21-5p tar-
get genes, we measured their expression by quantitative RT-PCR 
and by western blotting after ectopic expression of miR-15a-5p and 
miR-21-5p. Increased level of both miRNAs upon transfection was 
confirmed by qRT-PCR (Figure S2A).
miR-15a-5p and miR-21-5p overexpression significantly reduced 
ARL2, PDCD4 and BTG2 mRNA expression in K562 cells treated with 
cytarabine and daunorubicin (Figure 3A). The overexpression of 
miR-15a-5p or miR-21-5p in K562 cells treated with cytarabine and 
daunorubicin resulted in down-regulation of PDCD4 at the protein 
level with respect to the scrambled control (Figure 3B,C). ARL2 
expression was also decreased after overexpression of miR-15a-5p 
only (Figure 3B,C). Noticeably, we could not detect BTG2 expres-
sion by western blotting by processing with the available commer-
cial antibodies. The same results were obtained in K562 cell lines 
treated with cytarabine alone or daunorubicin alone versus vehicle 
(Figure S9).
We cloned the 3′UTR of ARL2, PDCD4 and BTG2 containing 
the seed sequences that were predicted to interact with miR-
15a-5p and miR-21-5p into a luciferase reporter vector pGL3 con-
trol (Figure S10). We cotransfected the luciferase reporter with 
the synthetic miRNA of interest into K562 cell line. There are two 
predicted interaction sites for miR-15a-5p in the PDCD4 3′UTR, 
five in the ARL2 3′UTR and two in the BTG2 3′UTR (Figure S10). 
The miR-21-5p has one predicted interaction site in the PDCD4 
3′UTR and one in the BTG2 3′UTR (Figure S10). A significant re-
duction in the luciferase/βgal ratio was observed for ARL2, PDCD4 
and BTG2 constructs transfected with synthetic miRNA compared 
with the control (Figure 3D). This effect was abrogated when we 
cotransfected mutated 3′UTR luciferase reporter vectors and the 
synthetic miRNA. The mutations were created by the deletion of 
4-6 bases in the seed sequence of the miRNAs (Figure S10). These 
results confirmed the direct regulation of the three target genes 
by miR-15a-5p and/or miR-21-5p.
3.4 | Target gene validation in patient samples
To validate the three target genes in our patient cohort, we analysed 
the data from the gene expression profiles performed on patient 
samples. Figure 4A shows the down-regulation of the three target 
F I G U R E  2   miR-15a-5p and miR-21-5p reduce apoptosis induced by the combination of cytarabine and daunorubicin. K562 cells were 
infected with lenti-miR virus to overexpress miR-15a-5p, miR-21-5p or EV. Annexin V assay was performed after 24 h of treatment with 
cytarabine (Ara-C) and daunorubicin (DNR). The results are presented as percentage of apoptotic cells. One representative experiment 
is shown in (A) and the average of th independent experiments ± SD in (B). P values were obtained using a t test. * Indicates a significant 
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genes in chemoresistant AML patients compared with chemosensi-
tive. The same results were observed in our smaller cohort of pa-
tients after the exclusion of the patients with ASXL1 and RUNX1 
mutation following the ELN2017 risk stratification (data not shown).
We performed a PCA based on selected gene and miRNA ex-
pression data. The first three principal components explained 
eighty-four per cent of the variance. Figure 4B shows the PCA plot 
of PC2 to PC1 (the two principal components). Individuals such as 
“54r”, “50”, “47”, “46” and “48” are chemoresistant and clearly sepa-
rated from the rest. Individuals “20”, “31”, “30”, “40”, “36” and “17” 
are chemosensitive and clearly separated from the rest. A separa-
tion of the two phenotypes (chemoresistant: the left side of the plot 
versus chemosensitive: the right side of the plot) can be observed. 
However, the separation between the phenotypes is still hard to 
achieve for some patients (the middle of the plot). The PC3 versus 
PC1 plot captured the separation of the same chemoresistant indi-
viduals that were clearly separated from the chemosensitive individ-
uals in the PC2 versus PC1 plot (Figure S11).
Figure 4C shows the correlation plot of the selected miRNAs and 
genes. The two miRNAs were clustered together, and the probesets 
were clustered per their corresponding genes. The plot shows a neg-
ative correlation based on the axis of PC1 between the two miRNAs 
and the BTG2 gene. A negative correlation between the two miRNAs 
and the ARL2 gene is also demonstrated based on the PC2 axis. For 
the PDCD4 gene, some probesets show more negative correlation 
with the two miRNAs according to the PC1 axis. In summary, based 
on the combination of the two first principal components we could 
distinguish a negative correlation between the expression of the two 
miRNAs and the three target genes.
3.5 | miR-15a-5p and miR-21-5p induce 
chemoresistance by targeting ARL2, PDCD4 and BTG2
To confirm the direct roles of the three target genes in chemoresist-
ance, we silenced ARL2, PDCD4 and BTG2 in K562 cells. K562 cells 
were transfected with a combination of three siRNAs against the 
three target genes (siARL2, siPDCD4 and siBTG2) at a concentration 
of 50 nmol/L each. We used a reduced concentration as the common 
100 nmol/L concentration was too toxic for the cell line. The effi-
ciency of the siRNAs was evaluated by western blotting for PDCD4 
and ARL2 and by qRT-PCR for the three target genes at 24 hours 
(Figure S3). After 24 hours of transfection, K562 cells were treated 
with cytarabine and daunorubicin. Chemosensitivity was assessed 
by apoptosis by an Annexin V test. The percentage of Annexin-
positive cells significantly decreased after the combined inhibition 
of the three target genes (Figure 5). This was not observed after the 
inhibition of only two of the three target genes such as PDCD4 and 
ARL2 (data not shown). The same effect on chemosensitivity was ob-
served after treatment of the cells with cytarabine or daunorubicin 
alone (Figure S12). In conclusion, inhibiting the three target genes 
reproduced the functional effects of both miRNAs.
4  | DISCUSSION
Acute myeloid leukaemia is only cured in 35%-40% of young 
adults. The main problem remains resistance to the old commonly 
used chemotherapy combining cytarabine and an anthracycline, 
that is daunorubicin. This paper provides new evidence of the 
important roles of miRNAs in chemoresistance in cytogenetically 
normal AML patients mediated by target genes implicated in early 
apoptosis.
In the present study, we demonstrated that miR-15a-5p and miR-
21-5p are significantly overexpressed in a cohort of chemoresistant 
compared with chemosensitive cytogenetically normal AML pa-
tients with wild-type NPM1 without FLT3-ITD. Our gain-of-function 
experiments in AML cell lines showed that miR-15a-5p or miR-21-5p 
overexpression decreases apoptosis after daunorubicin and/or cy-
tarabine treatment to almost reach the level of untreated cells. We 
found three interesting genes with a pro-apoptotic function. We con-
firmed that PDCD4, BTG2 and ARL2 are responsible for miR-15a-5p 
and miR-21-5p modulating effect on chemosensitivity of leukaemic 
cells to cytarabine and daunorubicin. The effect on chemosensitivity 
was stronger when the cells were treated with the combination of 
cytarabine and daunorubicin such as the treatment of the patients 
TA B L E  2   List of most down-regulated mRNAs after miR-15a-5p or miR-21-5p overexpression in K562 cells
Probe Set ID mir21 vs scramble log-ratio mir21 vs scramble log-ratio Gene symbol Gene description
TC01001685.hg.1 −0.206044 −0.707511 BTG2 BTG family, member 2




mir15 vs scramble 
log-ratio
mir15 vs scramble 
log-ratio Gene symbol Gene description
TC11003457.hg.1 −1.104408 −1.205423 ARL2 ADP ribosylation factor-
like 2
TC01001685.hg.1 −0.028212 −0.888098 BTG2 BTG family, member 2
TC10000808.hg.1 −0.268 −0.843751 PDCD4 Programmed cell 
death 4 (neoplastic 
transformation inhibitor)
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than with each drug alone. The most differentially down-regulated 
genes after miR-15a-5p or miR-21-5p overexpression in our AML cell 
lines treated with daunorubicin are PDCD4, BTG2 and ARL2. It seems 
that the expression of both miRNAs was positively correlated in our 
patient series supporting a synergistic role on the same target genes 
and on chemoresistance. No common mechanism of deregulation 
has been described for both miRNAs. Moreover, a negative correla-
tion between the expression of both miRNAs and the three target 
genes was confirmed in patient samples. Our data suggest that sev-
eral miRNAs can modulate chemosensitivity of myeloid leukaemia 
cells to cytarabine and/or daunorubicin by targeting the same genes.
Based on PCA performed on miRNA and gene expression, some 
patients could be phenotypically separated in chemoresistant or 
chemosensitive. Although we observed a tendency for phenotype 
separation, other patients could not be segregated as their expres-
sion profile for the selected genes and miRNAs was intermediate. 
Mechanisms affecting their expression need to be further explored. 
We cannot exclude additional mechanisms of chemoresistance in 
this group of unsegregated patients.
These three target genes have been previously linked to chemo-
resistance. PDCD4 (programmed cell death 4) is a tumour suppres-
sor gene that not only inhibits proliferation, migration and invasion 
but also promotes apoptosis in tumours.17 Zhang et al. showed that 
PDCD4 overexpression activate BAX (member of BCL2 protein 
family) that induces apoptosis in hepatoma cells.18 Knockdown of 
PDCD4 was shown to promote resistance to chemotherapy in dif-
ferent types of cancer cells, and PDCD4 was a functional target for 
miR-21–induced chemoresistance in tongue squamous carcinoma 
cells.19 ARL2 (ADP ribosylation factor-like 2) is a small GTP protein 
of the RAS superfamily whose increased expression was correlated 
with reduced aggressiveness of breast tumour cells.20 Breast can-
cer cells expressing low level of ARL2 were not sensitive to contact 
F I G U R E  3   miR-15a-5p and miR-21-5p regulate the expression of ARL2, PDCD4 and BTG2. A, Quantitative RT-PCR of PDCD4, ARL2 and 
BTG2 in K562 after 24 h of transfection with synthetic miR-15a-5p, miR-21-5p or SCR treated with cytarabine and daunorubicin. The results 
are shown as average mRNA expression after normalization with GAPDH and 2ΔCt calculations. B, Western blotting of PDCD4 and ARL2 
protein expression in K562 cells treated with cytarabine and daunorubicin after 24 h of transfection with synthetic miR-15a-5p, miR-21-5p 
or SCR. The protein loading control was performed using β-actin. C, Bands were quantified by densitometry using Image J software. Data 
represent the average of three independent experiments ± SD. P values were obtained using a t test. * Indicates a significant difference 
P ≤ .05, and ** indicates a significant difference P ≤ .01. D, Luciferase activity in HEK293 cells cotransfected with synthetic miR-15a-5p, miR-
21-5p or SCR and luciferase reporter constructs containing wild-type (WT) or mutated (miRNA_Δ) PDCD4, ARL2 and BTG2 3′UTR. Luciferase 
activities were determined at 24 h and were normalized using β-galactosidase activity. The mutant plasmids were generated by deleting the 
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inhibition, had a stronger clonogenic potential and an enhanced tu-
mour growth.20 Decreased ARL2 expression was associated with 
resistance to cytotoxic agents in breast cancer cell lines.21 In glioma 
cells, Wang et al. showed that ARL2 is an important suppressor of 
proliferation.22 BTG2 (B cell translocation gene 2) and BTG1 (B cell 
translocation gene 1) belong to the B cell translocation gene family 
of anti-proliferation proteins and regulate apoptosis, cell cycle pro-
gression and differentiation. The expression of BTG1 was induced in 
CR AML patients and was decreased in refractory AML patients.23 
Interestingly, Tong et al reported that miR-21 could protect cardio-
myocytes against doxorubicin-induced apoptosis by targeting BTG2, 
confirming our observations.24
miR-21 has been shown to drive chemoresistance by targeting 
PDCD4, PTEN or other genes in several solid tumours, such as renal 
carcinoma, hepatocellular carcinoma, colon carcinoma and gastric 
cancer cells.25-27 miR-21 was also found consistently up-regulated in 
AML blasts compared with normal CD34+ cells.28 No study had spe-
cifically investigated the role of miR-21 in chemoresistance in AML 
patients, but Bai et al found in 2011 that miR-21 overexpression in 
AML cell lines induced daunorubicin resistance in K562 by targeting 
PTEN.29 Li et al30 reported that miR-21 inhibition sensitizes AML cell 
lines to cytarabine by inducing apoptosis. These effects seemed to 
be partially because of the up-regulation of PDCD4.30 miR-15a was 
initially found down-regulated in a subgroup of chronic lymphocytic 
leukaemia patients.31 Little is known about the role of miR-15a in 
chemoresistance. In AML patients, high expression of miR-15a has 
been shown to predict shorter survival and worse response to 
chemotherapy.32
Finally, there is an urgent need to develop new therapeutic ap-
proaches in AML. miRNAs can modulate multiple signalling path-
ways and regulatory networks in AML.33 Slight changes in miRNA 
expression could be responsible for significant changes in treatment 
response. Modifying miRNA expression may target different path-
ways in AML blasts and avoid the development of chemoresistance. 
miR-15a-5p and miR-21-5p could be used as future targets for ther-
apy. Synthetic miRNAs are now involved in phase 1 and phase 2 clin-
ical trials. For example, MRG-106 is an LNA antagomir that targets 
miR-155 and is now tested in the treatment of selected types of 
lymphoma or leukaemia.34 Our results suggested a promising fur-
ther therapeutic option that will combine anti-miR-15a-5p and/or 
F I G U R E  4   Target gene validation in patient samples. A, Expression of PDCD4, ARL2andBTG2 was analysed by gene expression profiles 
(Affymetrix) in AML patients, with normal karyotype, sensitive (n = 27) or resistant (n = 16) to standard chemotherapy treatment combining 
cytarabine and daunorubicin. The box plot is based on microarray normalized mRNA expression. B, PCA based on selected gene and miRNA 
expression data were performed in R program using the mixOmics package. The PCA plot of PC2 to PC1 is shown in (B). The correlation plot 
of the miRNAs and genes used to perform the PCA is shown in (C)
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anti-miR-21-5p with standard induction chemotherapy to improve 
remission rate and decrease relapse rate mainly in chemoresistant 
AML patients.
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